Open AccessSafety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program
Author(s) -
Lisa Lancaster,
Lake Morrison,
Alexander Auais,
Beiying Ding,
Ahmar Iqbal,
Boris Polman,
Kevin R. Flaherty
Publication year - 2017
Publication title -
pulmonary therapy
Language(s) - English
Resource type - Journals
eISSN - 2364-1746
pISSN - 2364-1754
DOI - 10.1007/s41030-017-0049-z
Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , clinical trial , adverse effect , nausea , expanded access , gastroenterology , surgery , lung
In phase 3 clinical trials, pirfenidone significantly slowed disease progression with a well-defined and medically manageable safety profile in patients with idiopathic pulmonary fibrosis (IPF). This study examined safety events related to pirfenidone in patients with IPF in an expanded access program in the US.